 PALO ALTO, Calif., June 01, 2021 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. Nasdaq: BBIO, a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that the U.S. Food and Drug Administration FDA granted Fast Track designation for encaleret for the treatment of autosomal dominant hypocalcemia ADH1. The FDA Fast Track designation program is designed to facilitate the development and to expedite the review of new therapies hoping to treat or prevent serious conditions and fill an unmet medical need. BridgeBio announced the Fast Track designation on World Hypoparathyroidism Awareness Day, an annual global awareness and education event designed to spotlight and support people living with ADH1 and other types of hypoparathyroidism. 